NZ630644A - Methods for treating conditions associated with masp-2 dependent complement activation - Google Patents

Methods for treating conditions associated with masp-2 dependent complement activation

Info

Publication number
NZ630644A
NZ630644A NZ630644A NZ63064414A NZ630644A NZ 630644 A NZ630644 A NZ 630644A NZ 630644 A NZ630644 A NZ 630644A NZ 63064414 A NZ63064414 A NZ 63064414A NZ 630644 A NZ630644 A NZ 630644A
Authority
NZ
New Zealand
Prior art keywords
amino acid
acid sequence
heavy
light
chain cdr
Prior art date
Application number
NZ630644A
Inventor
Thomas Dudler
Gregory A Demopulos
Hans-Wilhelm Schwaeble
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of NZ630644A publication Critical patent/NZ630644A/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

Disclosed it the use of a composition comprising an amount of a MASP-2 inhibitory antibody, or antigen-binding fragment thereof, effective to inhibit thrombus formation in a human subject in the acute phase or in the remission phase of atypical hemolytic uremic syndrome (aHUS), in the manufacture of a medicament for treating a human subject in the acute phase or in the remission phase of aHUS, wherein said MASP-2 inhibitory antibody, or antigen-binding fragment thereof, comprises: (I) (a) a heavy-chain variable region comprising: i) a heavy chain CDR-H1 comprising the amino acid sequence RGKM; and ii) a heavy-chain CDR-H2 comprising the amino acid sequence LAHIFSSDEKSYRTS; and iii) a heavy-chain CDR-H3 comprising the amino acid sequence YYCARIR and (b) a light-chain variable region comprising: i) a light-chain CDR-L1 comprising the amino acid sequence GEKLGDKYAY; and ii) a light-chain CDR-L2 comprising the amino acid sequence DKQRPS; and iii) a light-chain CDR-L3 comprising the amino acid sequence AWDSSTAV, or (II) a variant thereof comprising a heavy-chain variable region with at least 90% identity to SEQ ID NO:67 and a light-chain variable region with at least 90% identity to SEQ ID NO:70.
NZ630644A 2014-07-03 2014-09-10 Methods for treating conditions associated with masp-2 dependent complement activation NZ630644A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462020845P 2014-07-03 2014-07-03

Publications (1)

Publication Number Publication Date
NZ630644A true NZ630644A (en) 2016-07-29

Family

ID=56506502

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630644A NZ630644A (en) 2014-07-03 2014-09-10 Methods for treating conditions associated with masp-2 dependent complement activation

Country Status (1)

Country Link
NZ (1) NZ630644A (en)

Similar Documents

Publication Publication Date Title
PH12021550023A1 (en) Humanized anti-tau antibodies
JP2018507220A5 (en)
CO2018004532A2 (en) Human anti-cd19 antibodies with high affinity
NZ631007A (en) Anti-c5 antibodies having improved pharmacokinetics
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
JP2017534577A5 (en)
PE20161571A1 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
PH12018500708A1 (en) Humanized anti-human cd19 antibodies and methods of use
MX2018014714A (en) Compositions for inhibiting masp-2 dependent complement acitivation.
MX2021011489A (en) Anti-claudin 18.2 antibody and application thereof.
AU2018290532A1 (en) Immunotherapy for hepatocellular carcinoma
JP2017528476A5 (en)
NZ629829A (en) Anti-c5a antibodies and methods for using the antibodies
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
AR102594A1 (en) ANTI-IL-1b ANTIBODIES AND METHODS OF USE
MX341958B (en) Antibodies against human il33r and uses thereof.
WO2014186622A3 (en) Methods of treatment for guillain-barre syndrome
PE20181051A1 (en) ANTI-EPHA4 ANTIBODY
NZ599779A (en) Compositions and methods for treating inflammatory disorders
MX2020007406A (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof.
JP2016530223A5 (en)
JP2016527225A5 (en)
WO2014172591A3 (en) Humanized antibody against interleukin-20 and treatment for inflammatory diseases
WO2012139069A3 (en) Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2019 BY COMPUTER PACKAGES INC

Effective date: 20180818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2020 BY COMPUTER PACKAGES INC

Effective date: 20190820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2021 BY COMPUTER PACKAGES INC

Effective date: 20200818

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2022 BY COMPUTER PACKAGES INC

Effective date: 20210817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2023 BY COMPUTER PACKAGES INC

Effective date: 20220817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2024 BY COMPUTER PACKAGES INC

Effective date: 20230817